Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: Implications

Leukemia Research

Volumn 27, Issue 9, 2003, Pages 853-857

  Ravandi, Farhad ^a   Verma, Amit ^a   Ridgeway, Jean ^a   Pursell, Kenneth ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

CLL; HIV; T cell dysfunction

Indexed keywords

ALEMTUZUMAB; ANTIRETROVIRUS AGENT; CD19 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; FLUDARABINE;

AGED; ARTICLE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; DEATH; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LABORATORY TEST; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0038541811     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00004-3     Document Type: Article

References (27)

1. Reed J.C. Molecular biology of chronic lymphocytic leukemia. Semin. Oncol. 25:1998;11-18.
2. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig (VH) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1999;1848-1854.
3. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davis Z., Thomas P.W., Stevenson F.K.et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 99:2002;1023-1029.
4. Ibrahim S., Keating M., Do K.A., O'Brien S., Huh Y.O., Jilani I.et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 98:2001;181-186.
5. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L.et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl. J. Med. 343:2000;1910-1916.
6. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1999;1840-1847.
7. Reed J.C. Molecular biology of chronic lymphocytic leukemia: implications for therapy. Semin. Hematol. 35:1998;3-13.
8. Kipps T.J., Chu P., Wierda W.G. Immunogenetic therapy for B-cell malignancies. Semin. Oncol. 27:2000;104-109.
9. Ghia P, Caligaris-Cappio F. The origin and nature of the chronic lymphocytic leukemia lymphocyte. In: Cheson BD, editor, Chronic lymphoid leukemias. 2nd ed. New York, Basel: Marcl Dekker; 2001. p. 63-80.
10. Pizzolo G., Chilosi M., Ambrosetti A., Semenzato G., Fiore-Donati L., Perona G. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood. 62:1983;1289-1296.
11. Kitada S., Zapata J.M., Andreeff M., Reed J.C. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 106:1999;995-1004.
12. Romano M.F., Lamberti A., Tassone P., Alfinito F., Costantini S., Chiurazzi F.et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood. 92:1998;990-995.
13. Krammer P.H. CD95's deadly mission in the immune system. Nature. 407:2000;789-795.
14. Osorio L.M., Aguilar-Santelises M. Apoptosis in B-chronic lymphocytic leukaemia. Med. Oncol. 15:1998;234-240.
15. Wang D., Freeman G.J., Levine H., Ritz J., Robertson M.J. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br. J. Haematol. 97:1997;409-417.
16. Panayiotidis P., Ganeshaguru K., Foroni L., Hoffbrand A.V. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia. 9:1995;1227-1232.
17. Chu P., Wierda W.G., Kipps T.J. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood. 95:2000;3853-3858.
18. Cloyd M.W., Chen J.J., Adeqboyega P., Wang L. How does HIV cause depletion of CD4 lymphocytes? A mechanism involving virus signaling through its cellular receptors. Curr. Mol. Med. 1:2001;545-550.
19. Levine AM, Scadden DT, Zaia JA, Krishnan A. Hematologic aspects of HIV/AIDS. Hematology (Am Soc Hematol Educ Prog) 2001;463-78.
20. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:2001;75-82.
21. Klein G, Klein E. Epstein-Barr virus and human lymphomas. In: Canellos GP, Lister TA, Sklar JL, editors. The lymphomas. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: Saunders; 1998. p. 63-73.
22. Goedert J.J. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin. Oncol. 27:2000;390-401.
23. Knowles D.M., Chamulak G.A., Subar M., Burke J.S., Dugan M., Wernz J.et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986). Ann. Intern Med. 108:1988;744-753.
24. Kaplan M.H., Susin M., Pahwa S.G., Fetten J., Allen S.L., Lichtman S.et al. Neoplastic complications of HTLV-III infection. Lymphomas and solid tumors. Am. J. Med. 82:1987;389-396.
25. Analo H.I., Akanmu A.S., Akinsete I., Njoku O.S., Okany C.C. Seroprevalence study of HTLV-1 and HIV infection in blood donors and patients with lymphoid malignancies in Lagos, Nigeria. Cent. Afr. J. Med. 44:1998;130-134.
26. Rossi P., Carbonari M., Bonomo R., Galli M., Manconi P.E., Scarpati B.et al. Epidemiological aspects of HTLV-III infection in Italy. Eur. J. Epidemiol. 1:1985;288-293.
27. Levine A.M., Sadeghi S., Espina B., Tulpule A., Nathwani B. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer. 94:2002;1500-1506.